Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMgc Pharma Ltd Regulatory News (MXC)

Share Price Information for Mgc Pharma Ltd (MXC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 22.00
Bid: 21.00
Ask: 23.00
Change: 0.00 (0.00%)
Spread: 2.00 (9.524%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 22.00
MXC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Worldwide distribution agreement of ArtemiC Rescue

18 Feb 2021 07:00

RNS Number : 5498P
MGC Pharmaceuticals Limited
18 February 2021
 

18 February 2021

ASX Code: MXC

LSE Code: MXC

MGC Pharmaceuticals Ltd

Master Supply & Distribution agreement signed with Swiss PharmaCan AG for exclusive worldwide[1] distribution of ArtemiCTM Rescue

Key Highlights:

· Minimum three (3) year exclusive worldwide1 supply and distribution agreement signed with leading European nutraceuticals producer and distributor, Swiss PharmaCan AG, for the distribution of ArtemiC™ Rescue as a food supplement

· This agreement follows the completion of a successful phase II double-blind, placebo-controlled clinical trial on 50 COVID-19 patients across Israel and India that met all its primary and secondary endpoints

· Agreement includes minimum wholesale order quantity to MGC Pharma of 40,000 units of ArtemiC™ Rescue per quarter

· Initial wholesale order of 10,000 units received by MGC Pharma, which has a total retail market value of US$850,000 for Swiss PharmaCan AG

· MGC Pharma to also produce and provide daily dosage immune support supplement ArtemiC™ Support, for daily use.

· Swiss PharmaCan AG to exclusively distribute ArtemiC™ Rescue and ArtemiC™ Support worldwide1, with specific focus on countries currently reporting high numbers of COVID-19

· The Company has sufficient manufacturing capacity at its production facility in Slovenia to produce commercial scale batches of ArtemiC™ Rescue and ArtemiC™ Support for distribution by Swiss PharmaCan AG

· Additionally, Swiss PharmaCan AG has already secured agreement with Relay Medical Corp. (CSE: RELA) and Glow LifeTech Ltd. for exclusive North American and Caribbean sales and distribution rights for ArtemiC™ Rescue and ArtemiC™Prevention

· Swiss PharmaCan AG has also secured ONASIS Holdings Corp. (OTC: ONSS) as Master Distributor of ArtemiC™ Rescue and ArtemiC™ Prevention through their channels in USA and Central America.

MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce it has signed an exclusive master supply and distribution agreement (the 'Agreement') with leading European nutraceutical producer and distributor, Swiss PharmaCan AG ("SPC") for the sale and distribution of the Company's food supplement ArtemiC™ Product line. ArtemiC™ incorporates SPC's MyCell Enhanced™ delivery system technology.

ArtemiC™ is a clinically tested food supplement (nutraceutical, dietary supplement, natural health product) containing four natural based ingredients consisting of Artemisinin, Curcumin, Boswellia serrata, and Vitamin C.

This Agreement represents the first sales of ArtemiC™ as a food grade product and provides MGC Pharma direct access to the large and rapidly growing markets that are still reporting high numbers of COVID-19 cases.

The signing of this distribution agreement follows the completion of a phase II double-blind, placebo-controlled clinical trial on 50 COVID-19 patients, to evaluate the safety and efficacy of the anti-inflammatory product, ArtemiC™ Rescue in December 2020 (refer ASX release 15 December 2020). Results from the trail highlight that ArtemiC™ Rescue demonstrates the following advantages:

 

· A full safety and efficacy profile with no drug-adverse events

· The ability to prevent deterioration of COVID-19 patients and achieve faster clinical improvement

· The ability to assist in reducing the pressure on the medical system and support coping with hospitalised patients

· The ability to reduce symptoms and pain associated with COVID-19

· The versatility to be used in community as well as in hospitals

As the mechanism of action of ArtemiC™ Rescue is focused on the anti-inflammatory effect and reducing and prevention of cytokine storm, a wide spectrum of potential indications will be considered for future development.

The Agreement includes a minimum wholesale order quantity of 40,000 units of per quarter and an initial wholesale order of 10,000 has already been received from SPC. This initial 10,000 unit order equates to a retail market value of US$850,000 to SPC.

Under the terms of the agreement, MGC Pharma will provide ArtemiC™ Rescue to SPC to distribute as a food supplement worldwide (with the exception of excluded territories; Thailand, Myanmar, Israel, CIS countries and Ukraine). MGC Pharma will also produce and provide an additional supplement called ArtemiC™ Support which is specifically designed for daily consumption to support and maintain the strength of the human immune system.

Under the Agreement SPC will be responsible for the obtainment of all relevant permits, approvals, certificates and licenses as well as the marketing, advertising, promotion, certification, import and customs clearance in chosen distribution markets.

The Company will be responsible for providing ArtemiC™ Rescue and ArtemiC™ Support to SPC and has the ability to produce commercial scale batches of both products through its current manufacturing capacity and production facility in Slovenia.

SPC has subsequently secured agreement with Relay Medical Corp. (CSE: RELA) and Glow LifeTech Ltd. for exclusive North American and Caribbean sales and distribution rights for ArtmeiCTM, and ONASIS Holding Corp (OTC: ONSS) as a master distributor in the USA and Central America under the exclusive distribution agreement, highlighting the demand for the product globally.

Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: "Following the successful results achieved from our ArtemiC™ Phase II clinical trial in December last year, we are very pleased to have signed this Agreement with Swiss PharmaCan AG for the worldwide distribution of ArtemiC™ as a food supplement as It provides full product validation of ArtemiC™ and its therapeutic benefits."

Michel Fässler, CEO and Member of the Board of Swiss PharmaCan AG, commented: "We are very happy with the successful cooperation between MGC and Swiss PharmaCan AG. The potential of ArtemiC™ is unlimited and a viable, natural solution in the current crisis, offering to so many people possible help and alleviation of their suffering."

 

--Ends--

Authorised for release by the Board, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@mgcpharma.com.au  

 

UK PR Advisors - Tavistock

Charles Vivian

Tim Pearson

+44 207 920 3150

mgcpharma@tavistock.co.uk

 

UK Broker - Turner Pope

Andy Thacker

Andy.Thacker@TurnerPope.com

Zoe Alexander

Zoe.Alexander@TurnerPope.com

+44 20 3657 0050

Australian PR/IR Advisors - Media & Capital Partners

Rod Hinchcliffe (IR) +61 412 277 377

Rod.Hinchcliffe@mcpartners.com.au

 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

 

 

About Swiss PharmaCan AG

Micelle Technology AG, parent company of Swiss PharmaCan AG is a dynamic organization dedicated to R&D using natural active ingredients (i.e. vitamins and minerals) to improve human health. As one of the leading innovators of plant-based micelle concentrates, Micelle Technology AG offers a unique technology, which enables the company to harness the full potential of herbal active ingredients.

Website: www.swisspharmacan.ch

 

 


[1] Excluded territories; Thailand, Myanmar, Israel, CIS (Armenia, Belarus, Kazakhstan, Moldova, Russia, Tajikistan, Uzbekistan) and Ukraine

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTTPMFTMTIBMAB
Date   Source Headline
28th Mar 20249:12 amRNSPDMR Notification
28th Mar 20249:07 amRNSRefinancing of Convertible Securities Agreement
18th Mar 20248:23 amRNSResults of General Meeting
29th Feb 20249:36 amRNSHalf-year Report
19th Feb 20244:00 pmRNSUpdate - Application for Admission to Trading
13th Feb 202410:00 amRNSDispatch of General Meeting Documents
31st Jan 20247:30 amRNSDecember 2023 Quarter Activity Report
11th Jan 20249:54 amRNSDirector/PDMR Shareholding
22nd Dec 20239:09 amRNSCompany Update & Placing to Raise US$500,000
19th Dec 20237:57 amRNSArtemiCâ„¢ receives FDA Approval in Saudi Arabia
18th Dec 20239:06 amRNSNon-Deal Roadshow Presentation December 2023
1st Dec 20238:09 amRNSCorporate Update - Board and UK Adviser Changes
30th Nov 20239:08 amRNSResults of Shareholder’s Annual General Meeting
16th Nov 20231:51 pmRNSHolding(s) in Company
13th Nov 20239:15 amRNSHolding(s) in Company
9th Nov 202310:47 amRNSHolding(s) in Company
8th Nov 202311:52 amRNSHolding(s) in Company
8th Nov 202310:00 amRNSCapital Consolidation and US$7.9m Placement
1st Nov 202311:30 amRNSConsolidation and New Fund Raising
1st Nov 202311:03 amRNSMGC Secures US$7.9 Million In Firm Commitments
31st Oct 20239:32 amRNSDispatch of Annual General Meeting Documents
30th Oct 20237:16 amRNSSeptember 2023 Quarter Activity Report
25th Oct 20233:16 pmRNSResults of Shareholder’s General Meeting
9th Oct 202310:02 amRNSDate of AGM & Closing Date of Director Nominations
29th Sep 202310:40 amRNSAnnual Report for the year ended 30 June 2023
26th Sep 20237:36 amRNSLetter From the Managing Director
26th Sep 20237:35 amRNSDispatch of General Meeting Documents
12th Sep 20237:00 amRNSHolding(s) in Company
5th Sep 202312:34 pmRNSResults of Shareholder’s General Meeting
1st Sep 20237:30 amRNSChange of registry address notification
31st Aug 20238:44 amRNS30 June 2023 Preliminary Financial Report
30th Aug 20238:30 amRNSShare Purchase Plan Closed
15th Aug 20237:29 amRNSSPP – Extension of Closing Date
14th Aug 20237:00 amRNSPositive Pre-clinical Trial Results on CimetrA®
4th Aug 20239:10 amRNSDispatch of General Meeting Documents
3rd Aug 20232:23 pmRNSAustralian Prospectus & Share Purchase Plan
2nd Aug 202310:25 amRNSApplication for Admission to Trading
1st Aug 20238:56 amRNSMGC Pharma Launches Share Purchase Plan
31st Jul 20237:00 amRNSPermission for first import of Psilocybin
28th Jul 20239:05 amRNSResignation of Joint Company Secretary
28th Jul 20238:00 amRNSJune 2023 Quarter Activity Report and Cash Flow
21st Jul 202310:56 amRNSHolding(s) in Company
18th Jul 202311:41 amRNSPDMR Notification
14th Jul 20237:00 amRNS£0.7 million Fundraising
12th Jul 20237:00 amRNSFurther re AMC Places another $1M Order of ArtemiC
7th Jul 20237:00 amRNSAMC Places Another US$1M Order of ArtemiC™
3rd Jul 20237:00 amRNSReclassification of Psychedelic Compounds
30th Jun 20239:31 amRNSDetails of Company Address
30th Jun 20239:30 amRNSCompany Update
29th Jun 202310:22 amRNSResults of Shareholder’s General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.